A. Flynn

811 total citations
16 papers, 693 citations indexed

About

A. Flynn is a scholar working on Hematology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, A. Flynn has authored 16 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 7 papers in Surgery and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in A. Flynn's work include Heparin-Induced Thrombocytopenia and Thrombosis (5 papers), Blood Coagulation and Thrombosis Mechanisms (5 papers) and Platelet Disorders and Treatments (4 papers). A. Flynn is often cited by papers focused on Heparin-Induced Thrombocytopenia and Thrombosis (5 papers), Blood Coagulation and Thrombosis Mechanisms (5 papers) and Platelet Disorders and Treatments (4 papers). A. Flynn collaborates with scholars based in United Kingdom, Sweden and Australia. A. Flynn's co-authors include David A. Lane, Ulf Lindahl, L Thunberg, J. J. Denton, Elizabeth Thompson, Gunnar Pejler, H. Ireland, J. Randall Curtis, Hediye Erdjument‐Bromage and H Ireland and has published in prestigious journals such as Journal of Biological Chemistry, Biochemical Journal and Annals of the New York Academy of Sciences.

In The Last Decade

A. Flynn

16 papers receiving 630 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Flynn United Kingdom	11	292	231	214	200	184	16	693
G. Henrita van Zanten Netherlands	9	411 1.4×	64 0.3×	109 0.5×	172 0.9×	14 0.1×	11	559
A.F.H. Jie Netherlands	12	252 0.9×	73 0.3×	118 0.6×	79 0.4×	9 0.0×	16	563
K. Bykowska Poland	13	240 0.8×	57 0.2×	59 0.3×	71 0.4×	13 0.1×	44	486
Helena M. Jacobs United States	9	115 0.4×	89 0.4×	57 0.3×	51 0.3×	15 0.1×	10	722
JR Maynard United States	6	317 1.1×	42 0.2×	35 0.2×	59 0.3×	28 0.2×	7	504
Kenneth J. Clemetson Switzerland	7	407 1.4×	39 0.2×	86 0.4×	135 0.7×	12 0.1×	8	606
Laurence Vénisse France	11	188 0.6×	48 0.2×	43 0.2×	50 0.3×	32 0.2×	19	402
F Josso France	15	558 1.9×	70 0.3×	67 0.3×	47 0.2×	31 0.2×	73	845
Mikhail D. Smirnov United States	11	333 1.1×	101 0.4×	62 0.3×	81 0.4×	13 0.1×	16	494
H Sandberg Sweden	8	445 1.5×	43 0.2×	51 0.2×	41 0.2×	34 0.2×	10	600

Countries citing papers authored by A. Flynn

Since Specialization

Citations

This map shows the geographic impact of A. Flynn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Flynn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Flynn more than expected).

Fields of papers citing papers by A. Flynn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Flynn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Flynn. The network helps show where A. Flynn may publish in the future.

Co-authorship network of co-authors of A. Flynn

This figure shows the co-authorship network connecting the top 25 collaborators of A. Flynn. A scholar is included among the top collaborators of A. Flynn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Flynn. A. Flynn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Flynn, A., Peter Galettis, Howard Gurney, et al.. (2024). Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists. Internal Medicine Journal. 54(9). 1458–1464. 3 indexed citations

Lane, David A., et al.. (1992). Antithrombotic Properties of Dermatan Sulphate (MF 701) in Haemodialysis for Chronic Renal Failure. Thrombosis and Haemostasis. 68(5). 563–569. 23 indexed citations

Lane, David A., et al.. (1991). Dose Finding Study of a Low Molecular Weight Heparin, Innohep, in Haemodialysis. Thrombosis and Haemostasis. 66(3). 277–282. 22 indexed citations

Ireland, H., et al.. (1990). A Low-Molecular-Weight Heparin (Kabi 2165, 'Fragmin') in Repeated Use for Haemodialysis: Prevention of Clotting and Prolongation of the Venous Compression Time in Comparison with Commercial Unfractionated Heparin. Nephrology Dialysis Transplantation. 5(2). 135–140. 27 indexed citations

Lane, David A., Hediye Erdjument‐Bromage, A. Flynn, et al.. (1989). Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis. British Journal of Haematology. 71(1). 91–96. 26 indexed citations

Lane, David A., et al.. (1989). Heparin and Low Molecular Weight Heparin(oid)s as Anticoagulants in Hemodialysis for Chronic Renal Failure. Annals of the New York Academy of Sciences. 556(1). 456–458. 2 indexed citations

Lane, David A., et al.. (1989). A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.. PubMed. 32(6). 290–6. 20 indexed citations

Lane, David A., et al.. (1988). Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.. PubMed. 543. 101–4. 1 indexed citations

Ireland, H., et al.. (1988). Low Molecular Weight Heparin in Haemodialysis for Chronic Renal Failure: Dose Finding Study of CY222. Thrombosis and Haemostasis. 59(2). 240–247. 17 indexed citations

10.

Lane, David A., G.D.O. Lowe, A. Flynn, et al.. (1987). Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis. British Journal of Haematology. 66(4). 523–527. 25 indexed citations

11.

Lane, David A., A. Flynn, H. Ireland, et al.. (1987). Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin. British Journal of Haematology. 65(4). 451–456. 32 indexed citations

12.

Lane, David A., G.D.O. Lowe, A. Flynn, et al.. (1987). ANTITHROMBIN III GLASGOW: A VARIANT WITH INCREASED HEPARIN AFFINITY AND REDUCED ABILITY TO INACTIVATE THROMBIN, ASSOCIATED WITH FAMILIAL THROMBOSIS. Thrombosis and Haemostasis. 2 indexed citations

13.

Lane, David A., Gunnar Pejler, A. Flynn, Elizabeth Thompson, & Ulf Lindahl. (1986). Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4.. Journal of Biological Chemistry. 261(9). 3980–3986. 168 indexed citations

14.

Lane, David A., et al.. (1986). On the Evaluation of Heparin and Low Molecular Weight Heparin in Haemodialysis for Chronic Renal Failure. Pathophysiology of Haemostasis and Thrombosis. 16(Suppl. 2). 38–47. 16 indexed citations

15.

Lane, David A., J. J. Denton, A. Flynn, L Thunberg, & Ulf Lindahl. (1984). Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochemical Journal. 218(3). 725–732. 308 indexed citations

16.

Flynn, A. & Patricia Fox. (1980). EVIDENCE FOR THE IDENTITY OF MILK LIPASE AND LIPOPROTEIN LIPASE. 4(2). 173–176. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact